Benzene Ring Containing Patents (Class 514/646)
  • Patent number: 10537521
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol about 25 mg and the second (and optionally) third doses are intravenously administered at intervals of about 2 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 hours, until the patient no longer requires treatment with tramadol.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: January 21, 2020
    Assignee: Revogenex Ireland Ltd.
    Inventor: Lucy Lu
  • Patent number: 10500280
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 10, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10182992
    Abstract: Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: January 22, 2019
    Assignee: Patheon Softgels Inc.
    Inventors: George Vamvakas, Aqeel A Fatmi
  • Patent number: 10166290
    Abstract: Inventor seeks patents related to the use in solid cancer patients of substances, (including, for example, dinitrohalogenated compounds) injected into tumor nodules in association with treatment with one or more checkpoint inhibitors that are administered before, during or after the intralesional (intratumoral) injection or injections.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: January 1, 2019
    Inventor: Max H. Cohen
  • Patent number: 10117868
    Abstract: A method of treating an ocular disorder in a subject includes administering to the subject subtherapeutic amounts of two or more agents that inhibit and/or blocks the activation of Gs- or Gq-protein coupled receptors or Gs- or Gq-signaling cascade in ocular cells of the subject, and/or activates Gi-protein coupled receptors, which is induced or triggered by light induced all-trans-retinal generation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: November 6, 2018
    Assignee: Case Western Reserve University
    Inventors: Krzysztof Palczewski, Yu Chen, Akiko Maeda
  • Patent number: 10022321
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol about 25 mg and the second (and optionally) third doses are intravenously administered at intervals of about 2 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 hours, until the patient no longer requires treatment with tramadol.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: July 17, 2018
    Assignee: Revogenex Ireland Ltd.
    Inventor: Lucy Lu
  • Patent number: 10022418
    Abstract: In alternative embodiments the invention provides compositions and methods for ameliorating diseases and conditions having a beta-amyloid component, including Alzheimer's disease (AD), Vascular Dementia (VD), dementia, pre-dementia, Cognitive Dysfunction Syndrome (CDS) and loss of cognition in humans and in non-human animal. In alternative embodiment the invention provides analogs of AB-007 and its acid form E64c (loxistatin), their preparation, and pharmaceutical compositions thereof and methods of making and using same. In alternative embodiments compositions of the invention are deuterated analogs of AB-007 (or E64d) and E64c (or loxistatin). In alternative embodiments compositions of the invention are metabolically blocked forms as compared to AB-007 and loxistatin. In alternative embodiments compositions of the invention are used to ameliorate (including treat, slow, reverse or prevent) a disease or condition which can be ameliorated by partial or complete inhibition of a cysteine protease, e.g.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: July 17, 2018
    Assignee: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.
    Inventors: Robert J. Ternansky, Amy Allan, Gregory Hook
  • Patent number: 9980900
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: May 29, 2018
    Assignee: Revogenex Ireland LTD
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Patent number: 9968551
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: May 15, 2018
    Assignee: Revogenex Ireland Ltd
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Patent number: 9901585
    Abstract: A pharmaceutical product or formulation, which comprises azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and a steroid, or a pharmaceutical acceptable salt, solvate or physiologically functional derivative thereof, preferably the product or formulation being in a form suitable for nasal or ocular administration.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: February 27, 2018
    Assignee: Cipla Limited
    Inventors: Amar Lulla, Geena Malhotra
  • Patent number: 9754211
    Abstract: A decision tree methodology based uplift modeling approach, wherein one decision tree is developed simultaneously on test and control groups with the objective of maximizing the mean-difference in identified subsets within the data. The incrementality modeling approach discussed may be applied in any situation where an incrementality model is required to determine who among a group of users should be exposed to a treatment with the goal of receiving a positive response.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: September 5, 2017
    Assignee: eBay Inc.
    Inventor: Andes Ozbay
  • Patent number: 9693949
    Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: July 4, 2017
    Assignee: REVOGENEX IRELAND LTD
    Inventors: Lucy Lu, Scott Reines, Jeffrey Ping
  • Patent number: 9649282
    Abstract: A composition formulated for diversion- and/or abuse-resistance, includes at least one active pharmaceutical ingredient (API), each present in an acidic form, a first compound capable of coupling to the acidic form of the API to form a complex, where the resulting complex is resistant to separation by conventional separation methods, and a second compound capable of preferentially coupling to the first compound to thereby release the API from the complex.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 16, 2017
    Assignee: Invincible Biotechnology, LLC
    Inventors: Vadim Zolotarsky, Alexandr Vasilievich Troitsky, Michael Libman, Mikhail Viktorovich Losev
  • Patent number: 9616034
    Abstract: The present invention relates to the administration of compositions comprising trans-clomiphene or an analog or salt thereof, for inhibiting bone resorption and bone turnover in a subject. The invention is also directed to methods for increasing bone mineral density in a subject and preventing or treating a bone related disorder in a subject comprising administering to the subject an effective amount of trans-clomiphene or an analog or salt thereof.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: April 11, 2017
    Assignee: REPROS THERAPEUTICS INC.
    Inventors: Joseph S. Podolski, Kuang Hsu, Ronald D. Wiehle, Greg Fontenot, Jaye Thompson
  • Patent number: 9616061
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: April 11, 2017
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence Wennogle
  • Patent number: 9586888
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 7, 2017
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • Patent number: 9573873
    Abstract: In a non-limiting embodiment, there is provided a compound of formula (I), which may permit for a method or use in treating or preventing a cancer, such as pancreatic cancer or leukemia. In one embodiment, there is also provide a method of preparing a compound of formula (Ia), the method including conducting a cyclization reaction of a compound of formula (III) to obtain a compound of formula (IV), wherein conducting the cyclization reaction comprises conducting a Michael reaction in the presence of a Lewis acid.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 21, 2017
    Inventors: James Green, Mariam Mehdi, Sinisa Djurdjevic
  • Patent number: 9522129
    Abstract: Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
    Type: Grant
    Filed: February 8, 2013
    Date of Patent: December 20, 2016
    Assignee: Velicept Therapeutics, Inc.
    Inventors: Stephen Caltabiano, Eliot Ohlstein, Stewart McCallum
  • Patent number: 9403767
    Abstract: The invention relates to compounds that have an affinity to the ?-opioid receptor and the ORL 1-receptor, methods for their production, medications containing these compounds and the use of these compounds for the treatment of pain and other conditions.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: August 2, 2016
    Assignee: GRUENENTHAL GMBH
    Inventors: Bert Nolte, Wolfgang Schröder, Klaus Linz, Werner Englberger, Hans Schick, Heinz Graubaum, Birgit Braun, Sigrid Ozegowski, József Bálint, Helmut Sonnenschein
  • Patent number: 9302981
    Abstract: The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 5, 2016
    Assignee: REVIVA PHARMACEUTICALS, Inc.
    Inventors: Laxminarayan Bhat, Seema Rani Bhat
  • Patent number: 9289392
    Abstract: There is provided an extended release pharmaceutical composition comprising from about 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also provides an extended release pharmaceutical composition comprising triple combination of from about 30 mg to about 300 mg of levodopa, 10 mg to about 100 mg of carbidopa and 200 mg to about 1000 mg of entacapone or salts thereof, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
    Type: Grant
    Filed: August 22, 2009
    Date of Patent: March 22, 2016
    Assignee: Wockhardt Ltd.
    Inventors: Ritesh Kapoor, Munish Talwar, Sanjay Mate, Manoj Mashalkar, Girish Kumar Jain, Mandar Kodgule
  • Patent number: 9226905
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a muscle wasting-related disease comprising diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a muscle wasting-related disease by increasing muscle mass, preventing muscle loss and effectively restoring muscle function.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: January 5, 2016
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Sang Chul Park, Sung Chun Cho, Young Hoon Son, Sun Gun Chung
  • Patent number: 9220706
    Abstract: A method of inhibiting the growth of leukemic hematopoietic stem cells in a subject with leukemia is described. The method includes administering a therapeutically effective amount of a composition including a compound of formula I: I wherein R1 is independently selected from hydrogen and methyl; R2 is selected from the group consisting of 4,8-dimethyl-non-1-enyl, 4,8-dimethyl-nonyl, non-1-enyl, and nonanyl groups; X is a carboxyl, phosphonic, or sulfonic moiety, and n is an integer from 1 to 6, or a compound of Formula II: II wherein R1 is a C6-C12 alkyl or C6-C12 alkoxy group; R2 is independently selected from the group consisting of hydrogen, methoxy, and hydroxyl; and R3 is an alkyl or cycloalkyl group; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 29, 2015
    Assignees: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), THE UNITED STATES OF AMERICA NIH DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY RESOURCES (DEITR)
    Inventors: Danilo Perrotti, Paolo Neviani
  • Patent number: 9212131
    Abstract: Novel polyamine transport inhibitors have been synthesized and demonstrated to block the uptake of native polyamines into human cancer cells. A combination therapy of the transport inhibitor and DFMO (a drug which blocks polyamine biosynthesis) provided synergistic activity against a metastatic human colon cancer cell line. The strategy uses polyamine depletion and polyamine metabolism to generate reactive oxygen species within cells as a novel way to treat cancers. This approach may be implemented for widespread use in the treatment of diseases which rely upon polyamine transport activity for proliferation.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: December 15, 2015
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Otto Phanstiel, Jennifer J. Archer
  • Patent number: 9168258
    Abstract: Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals and pharmaceutical compositions comprising them for the treatment of one or more disorders involving the 5-HT2A, SERT and/or dopamine D2 pathways are disclosed. In addition, the compounds may be combined with other therapeutic agents for the treatment of one or more sleep disorders, depression, psychosis, dyskinesias, and/or Parkinson's disease or any combinations.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: October 27, 2015
    Assignee: INTRA-CELLULAR THERAPRIES, INC.
    Inventors: Sharon Mates, Allen Fienberg, Lawrence P. Wennogle
  • Publication number: 20150148359
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Application
    Filed: May 22, 2013
    Publication date: May 28, 2015
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Patent number: 9040589
    Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9040590
    Abstract: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: May 26, 2015
    Assignee: NeuroDerm, Ltd.
    Inventors: Oron Yacoby-Zeevi, Mara Nemas
  • Patent number: 9028855
    Abstract: The present invention pertains to plant additives containing a molecule selected in a family of compounds, wherein said molecule can modulate some molecular markers and physiological modifications observed in cases of phosphate deficiency. The family of compounds comprises the molecule MC2 of formula as well as analogs thereof.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: May 12, 2015
    Assignee: Commissariat a l'Energie Atomique et aux Energies Alternatives
    Inventors: Mathilde Clement, Thierry Desnos, Laurent Nussaume
  • Patent number: 9011906
    Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Patent number: 9011905
    Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: April 21, 2015
    Assignee: Vivus, Inc.
    Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
  • Publication number: 20150099720
    Abstract: Provided herein are compounds having a structure selected from among Formula (I), Formula (II), Formula (III), Formula (IV), Formula (V) and Formula (VI) that are androgen receptor modulators and/or androgen receptor binding agents. Also disclosed are methods of making and using such compounds, including, but not limited to, using such compounds for treating various conditions.
    Type: Application
    Filed: October 20, 2014
    Publication date: April 9, 2015
    Inventors: Lin Zhi, Robert I. Higuchi, E. Adam Kallel, Cornelis Arjan Van Oeveren, Jyun-Hung Chen, Daniel A. Ruppar, Bijan Pedram, Thomas Lot Stevens Lau, Todd A. Miller
  • Publication number: 20150093438
    Abstract: There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub-analgesic amount is from about 60 to 80 mg, of tramadol or a salt thereof.
    Type: Application
    Filed: May 3, 2013
    Publication date: April 2, 2015
    Inventors: Malcolm Philip Young, Philip McKeown
  • Patent number: 8987290
    Abstract: The present invention concerns a needle-less drug delivery device being suitable for delivering drugs through a skin surface into a human or animal body comprising a pharmaceutical composition with at least one analgesic agent preferably being an opioid. The present invention also relates to the use of at least one analgesic agent, preferably being at least one opioid in a needle-less drug delivery device being suitable for injecting medication through a skin surface into the human or animal body. Further, the invention is concerned with a method of treating breakthrough pain by injecting at least one analgesic agent preferably being an opioid into the human or animal body using a needle-less drug delivery device.
    Type: Grant
    Filed: August 29, 2007
    Date of Patent: March 24, 2015
    Assignee: Purdue Pharma L.P.
    Inventor: Jo Woodward
  • Publication number: 20150080347
    Abstract: Disclosed is a concentrate for dilution comprising a S1P receptor agonist or a pharmaceutically acceptable salt thereof, propylene glycol and optionally glycerin. This formulation is adapted for patients in a difficult condition to swallow.
    Type: Application
    Filed: December 6, 2013
    Publication date: March 19, 2015
    Applicant: NOVARTIS AG
    Inventors: Vivian Georgousis, Wei-Qin Tong
  • Patent number: 8980223
    Abstract: Methods of inhibiting ischemia-related and ischemia-reperfusion-related injury are provided. Remote administration of a C-fiber activator or TRPV1 agonist or remote electrical stimulation and activation of TRPV1 reduces ischemia-related tissue damage in subjects at risk for ischemia-related tissue damage. In aspects of the invention, remote application of a TRPV1 agonist inhibits ischemia-related cardiac tissue damage. Methods of inhibiting cardiac tissue damage by topically administering the TRPV1 agonist, capsaicin are provided.
    Type: Grant
    Filed: May 7, 2010
    Date of Patent: March 17, 2015
    Assignee: University of Cincinnati
    Inventors: W. Keith Jones, Xiaoping Ren, Neal Lee Weintraub
  • Publication number: 20150073021
    Abstract: The present invention provides a method of inhibiting the binding of anthrax lethal factor with protective antigen comprising contacting the anthrax lethal factor with a compound having the structure:
    Type: Application
    Filed: September 5, 2014
    Publication date: March 12, 2015
    Applicants: The Research Foundation for The State University of New York, Chem-Master International, Inc.
    Inventors: Anthony ANTONELLI, Sanford R. SIMON, Yu ZHANG, Lorne M. GOLUB, Francis JOHNSON
  • Publication number: 20150040894
    Abstract: Aerosolized dapsone (or alternatively, an aqueous formulation of dapsone) is used to treat airway inflammation, particularly chronic neutrophil-dominated inflammation. Diseases that may be prevented or treated by the methods include chronic obstructive pulmonary diseases (COPDs), asthma, cystic fibrosis, and others.
    Type: Application
    Filed: October 22, 2014
    Publication date: February 12, 2015
    Applicant: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Bruce K. Rubin, Soichiro Kanoh, Tsuyoshi Tanabe
  • Publication number: 20150045437
    Abstract: Provided are kits containing a base composition and an active pharmaceutical ingredient for transdermal delivery of active pharmaceutical ingredients. Examples of active pharmaceutical ingredients include amitriptyline, baclofen, cyclobenzaprine HCl, ibuprofen, lidocaine HCl, naproxen and tramadol, ketoprofen, diclofenac, phenylbutazone, mefenamic acid, flubiprofen, piroxicam, guaifenasin, prilocaine, bupivicaine, tetracaine, nifedipine, verapamil, orphenadrine, imipramine, ketamine, gabapentin, carbamazepine, menthol, capsaicin, clonidine, dexamethasone, dextromethorphan, testosterone, progesterone, and estrogens.
    Type: Application
    Filed: August 8, 2014
    Publication date: February 12, 2015
    Inventor: Robert Prentice Nickell
  • Publication number: 20150038574
    Abstract: Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
    Type: Application
    Filed: November 29, 2012
    Publication date: February 5, 2015
    Applicant: Bikam Pharmaceuticals, Inc.
    Inventors: David S. Garvey, Judd Berman, Tan Quach
  • Patent number: 8946262
    Abstract: Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.
    Type: Grant
    Filed: November 29, 2004
    Date of Patent: February 3, 2015
    Assignee: Adolor Corporation
    Inventors: David D Christ, Bruce A Wallin, Deanne D Garver, William K Schmidt, David Jackson
  • Patent number: 8945603
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Grant
    Filed: January 29, 2014
    Date of Patent: February 3, 2015
    Assignee: Boston Foundation for Sight
    Inventor: Perry Rosenthal
  • Publication number: 20150031773
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a muscle wasting-related disease comprising diaminodiphenylsulfone (Dapsone; DDS) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition according to the present invention may be effectively used to prevent or treat a muscle wasting-related disease by increasing muscle mass, preventing muscle loss and effectively restoring muscle function.
    Type: Application
    Filed: December 7, 2012
    Publication date: January 29, 2015
    Inventors: Sang Chul Park, Sung Chun Cho, Young Hoon Son, Sun Gun Chung
  • Publication number: 20150030675
    Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
    Type: Application
    Filed: April 25, 2014
    Publication date: January 29, 2015
    Applicant: Valeant International Bermuda
    Inventors: Fang ZHOU, Paul MAES
  • Patent number: 8937090
    Abstract: The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin-inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and further provides an external composition for skin to which a compound having the above-mentioned function has been added. The parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent comprises one or more compounds selected from the group consisting of ?-alanine derivatives and salts thereof. The external composition for skin comprises the one or more compounds selected from the group consisting of ?-alanine derivatives and salts thereof as the above-mentioned parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/ameliorating agent.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: January 20, 2015
    Assignee: Shiseido Company, Ltd.
    Inventors: Mikiko Kaminuma, Masaru Suetsugu, Toshii Iida, Shinji Inomata
  • Publication number: 20150017250
    Abstract: The invention relates to a tamper-resistant, oral pharmaceutical dosage form comprising a pharmacologically active ingredient having psychotropic action and an ethylene-vinyl acetate (EVA) polymer which provides resistance against solvent extraction, resistance against grinding, and resistance against dose-dumping in aqueous ethanol.
    Type: Application
    Filed: July 10, 2014
    Publication date: January 15, 2015
    Applicant: GRÜNENTHAL GMBH
    Inventors: KLAUS WENING, LUTZ BARNSCHEID, SEBASTIAN SCHWIER, ANJA GEIßLER
  • Publication number: 20150018293
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Application
    Filed: May 12, 2014
    Publication date: January 15, 2015
    Applicant: NEWMARKET PHARMACEUTICALS LLC
    Inventors: David ROCK, Mark RIDALL
  • Patent number: 8932628
    Abstract: The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: January 13, 2015
    Assignee: Valeant International Bermuda
    Inventors: Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
  • Patent number: 8933129
    Abstract: The present teachings provide compounds of Formulae I and II: and pharmaceutically acceptable salts, hydrates, complexes, esters, and prodrugs thereof, wherein R1, R1?, R2, R2?, R3, R3?, and X are as defined herein. The present teachings also provide methods of making the compounds of formulae I and II, and methods of treating RyR-associated conditions, disorders, and diseases that include administering a therapeutically effective amount of a compound of formula I or II to a subject in need thereof. In addition, the present teachings relate to methods of reducing the open probability of a ryanodine receptor, and methods of reducing Ca2+ release across a ryanodine receptor (e.g., into the cytoplasm of a cell), by contacting a compound of formula I or II with a ryanodine receptor.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: January 13, 2015
    Assignee: State of Oregon by and through the State Board of Higher Education on behalf of Portland State University
    Inventors: Jonathan Abramson, Robert Strongin
  • Patent number: RE45907
    Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.
    Type: Grant
    Filed: February 13, 2014
    Date of Patent: March 1, 2016
    Assignees: OXiGENE, Inc., Baylor Universwity
    Inventors: David J. Chaplin, Charles Manly Garner, III, Robert Ronald Kane, Kevin G. Pinney, Joseph Anthony Prezioso, Klaus Edvardsen